Articles by Reflector - Pharmaceutical Executive

ADVERTISEMENT

Articles by Reflector

Reflector


Reflector is Pharm Exec Europe's man inside the EU.

Articles
Peril, Not Progress on Transatlantic Trade Deal
September 1, 2014

Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.

TTIP: From Hot Tip to Oblivion?
August 18, 2014

The Transatlantic Trade and Investment Partnership (TTIP) was the hot tip for a 2014 success story. But as summer slides away, the latest read-out of progress suggests that rather than remaining a hot tip, TTIP is now risking oblivion...

EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire?
August 1, 2014

Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.

Europe Gears Up to Attack Counterfeit Medicines—But Only Some of Them
July 1, 2014

Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.

Hopes High as EU Heads Into Leadership Change
June 1, 2014

Rare allies—innovator and generic pharmas—are calling for policy integration in Europe. But ideology and newfound scepticism on the merits of drugs in healthcare could complicate the effort.

Rebuilding European Pharma's Competitive Agenda
May 19, 2014

Because of the tougher conditions they face and shifts in ownership and corporate strategy, EFPIA and EGA have started to work together much more closely.

European Clinical Trials: The Die Is Cast
April 15, 2014

Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.

Whatever Happened To Faster Reimbursement For Generics In Europe?
April 1, 2014

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.

Italian Ruling on Roche and Novartis Resonates Across Europe
March 24, 2014

Roche and Novartis have been fined in Italy on pricing conspiracy charges, fueling a wider debate in Europe about expenditure, efficiency and off-label prescribing.

ADVERTISEMENT

Click here